Lexicon Pharmaceuticals, Inc.
LXRX
$0.3918
$0.02416.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 884.75% | 792.40% | 1,734.13% | 766.91% | 324.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 884.75% | 792.40% | 1,734.13% | 766.91% | 324.80% |
| Cost of Revenue | 25.43% | 26.41% | 22.90% | 11.66% | 5.02% |
| Gross Profit | -17.50% | -20.25% | -18.57% | -9.66% | -4.30% |
| SG&A Expenses | 46.82% | 74.35% | 116.07% | 137.05% | 140.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.84% | 55.38% | 73.27% | 71.41% | 62.42% |
| Operating Income | -35.95% | -53.05% | -71.34% | -70.45% | -62.08% |
| Income Before Tax | -37.08% | -54.61% | -75.34% | -73.74% | -62.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.08% | -54.61% | -75.34% | -73.74% | -62.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.08% | -54.61% | -75.34% | -73.74% | -62.64% |
| EBIT | -35.95% | -53.05% | -71.34% | -70.45% | -62.08% |
| EBITDA | -36.04% | -53.15% | -71.48% | -70.63% | -62.29% |
| EPS Basic | 0.62% | -13.88% | -31.39% | -29.29% | -20.53% |
| Normalized Basic EPS | 0.57% | -13.90% | -31.38% | -29.25% | -20.47% |
| EPS Diluted | 0.62% | -13.88% | -31.39% | -29.29% | -20.53% |
| Normalized Diluted EPS | 0.57% | -13.90% | -31.38% | -29.25% | -20.47% |
| Average Basic Shares Outstanding | 40.51% | 38.11% | 33.86% | 33.40% | 32.91% |
| Average Diluted Shares Outstanding | 40.51% | 38.11% | 33.86% | 33.40% | 32.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
